Literature DB >> 23429396

The SUVmax for (18)F-FDG correlates with molecular subtype and survival of previously untreated metastatic breast cancer.

Jian Zhang1, Zhen Jia, Min Zhou, Joseph Ragaz, Yong-Ping Zhang, Bi-Yun Wang, Zhong-Hua Wang, Xi-Chun Hu, Ying-Jian Zhang.   

Abstract

AIM: The objectives of this study were to determine if the baseline SUVmax measured by F-FDG PET/CT correlates with molecular subtype and to explore the impact of baseline SUVmax on the survival of patients with metastatic breast cancer (MBC).
METHODS: Patients with MBC were screened with PET/CT from February 2007 until December 2010. Multivariate linear regression analysis was performed to identify independent variable correlation with SUVmax. Prognostic variables identified by univariate analysis, with P < 0.1, were analyzed in the multivariate Cox model.
RESULTS: A total of 244 MBC patients were eligible for this study. Multivariate linear regression analysis showed that molecular subtype, visceral metastasis, and number of metastatic organs could be used to predict the logarithmic values of SUVmax (lgSUVmax) for previous untreated MBC patients, whereas for those with 1 or more line previous treatment, the number of metastatic organs was identified as the only independent variable correlating with lgSUVmax. Cox regression analysis indicated that only in patients with previously untreated MBC did baseline SUVmax (continuous variable) act as an independent prognostic factor (hazard ratio = 1.049 for progression-free survival, 1.124 for overall survival).
CONCLUSIONS: Baseline SUVmax correlates with molecular subtypes only in previously untreated MBC patients. PET/CT imaging can be used as a potential prognostic tool for patients with newly diagnosed MBC.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23429396     DOI: 10.1097/RLU.0b013e3182816318

Source DB:  PubMed          Journal:  Clin Nucl Med        ISSN: 0363-9762            Impact factor:   7.794


  7 in total

1.  PET/CT and breast cancer subtypes.

Authors:  Laura Gilardi; Marco Colleoni; Giovanni Paganelli
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-09       Impact factor: 9.236

2.  Could semiquantitative FDG analysis add information to the prognosis in patients with stage II/III breast cancer undergoing neoadjuvant treatment?

Authors:  Laura Evangelista; Anna Rita Cervino; Cristina Ghiotto; Tania Saibene; Silvia Michieletto; Bozza Fernando; Enrico Orvieto; Valentina Guarneri; Pierfranco Conte
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-05-31       Impact factor: 9.236

3.  The Role of (18)F-FDG PET/CT as a Prognostic Factor in Patients with Synovial Sarcoma.

Authors:  Kyoung Jin Chang; Ilhan Lim; Joon Yeun Park; A Ra Jo; Chang Bae Kong; Won Seok Song; Wan Hyeong Jo; Soo Yong Lee; Jae Soo Koh; Byung Il Kim; Chang Woon Choi; Sang Moo Lim
Journal:  Nucl Med Mol Imaging       Date:  2014-10-30

4.  Whole-body total lesion glycolysis measured on fluorodeoxyglucose positron emission tomography/computed tomography as a prognostic variable in metastatic breast cancer.

Authors:  Yoko Satoh; Atsushi Nambu; Tomoaki Ichikawa; Hiroshi Onishi
Journal:  BMC Cancer       Date:  2014-07-21       Impact factor: 4.430

5.  Prognostic Significance of Standardized Uptake Value on 18Fluorine-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Patients with Nasopharyngeal Carcinoma.

Authors:  Şeyda Türkölmez; Sabire Yılmaz Aksoy; Elif Özdemir; Zuhal Kandemir; Nilüfer Yıldırım; Atiye Yılmaz Özsavran; Mehmet Faik Çetindağ; Kenan Köse
Journal:  World J Nucl Med       Date:  2017 Jan-Mar

Review 6.  Application of PET Tracers in Molecular Imaging for Breast Cancer.

Authors:  Jorianne Boers; Erik F J de Vries; Andor W J M Glaudemans; Geke A P Hospers; Carolina P Schröder
Journal:  Curr Oncol Rep       Date:  2020-07-06       Impact factor: 5.075

7.  Prognostic Value of Dual-Time-Point 18F-Fluorodeoxyglucose PET/CT in Metastatic Breast Cancer: An Exploratory Study of Quantitative Measures.

Authors:  Mohammad Naghavi-Behzad; Charlotte Bjerg Petersen; Marianne Vogsen; Poul-Erik Braad; Malene Grubbe Hildebrandt; Oke Gerke
Journal:  Diagnostics (Basel)       Date:  2020-06-11
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.